Aging and bone loss: new insights for the clinician:
TLDR
New evidence on the pathophysiology of age-related bone loss with emphasis upon the mechanism of action of current osteoporosis treatments is reviewed, including therapeutic approaches to osteoporeosis in the elderly that focus on thePathophysiology and potential reversal of adipogenic shift in bone.Abstract:
It is well known that the underlying mechanisms of osteoporosis in older adults are different than those associated with estrogen deprivation. Age-related bone loss involves a gradual and progressive decline, which is also seen in men. Markedly increased bone resorption leads to the initial fall in bone mineral density. With increasing age, there is also a significant reduction in bone formation. This is mostly due to a shift from osteoblastogenesis to predominant adipogenesis in the bone marrow, which also has a lipotoxic effect that affects matrix formation and mineralization. We review new evidence on the pathophysiology of age-related bone loss with emphasis upon the mechanism of action of current osteoporosis treatments. New potential treatments are also considered, including therapeutic approaches to osteoporosis in the elderly that focus on the pathophysiology and potential reversal of adipogenic shift in bone.read more
Citations
More filters
Journal ArticleDOI
Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.
Chao Liang,Baosheng Guo,Heng Wu,Ningsheng Shao,Defang Li,Jin Liu,Lei Dang,Cheng Wang,Hui Li,Shaohua Li,Wing Ki Lau,Yu Cao,Zhijun Yang,Cheng Lu,Xiaojuan He,Doris W.T. Au,Xiaohua Pan,Bao-Ting Zhang,Changwei Lu,Hong Qi Zhang,Kinman Yue,Airong Qian,Peng Shang,Jiake Xu,Lianbo Xiao,Zhaoxiang Bian,Weihong Tan,Zicai Liang,Fuchu He,Lingqiang Zhang,Aiping Lu,Ge Zhang +31 more
TL;DR: The results indicate that osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strategy, advancing the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level.
Journal ArticleDOI
Immunology of Osteoporosis: A Mini-Review
Peter Pietschmann,Diana Mechtcheriakova,Anastasia Meshcheryakova,Ursula Föger-Samwald,Isabella Ellinger +4 more
TL;DR: Osteoporosis is a major cause of fractures and associated morbidity in the aged population and oxidative stress and the generation of advanced glycation end products have emerged as links between inflammation and bone destruction.
Journal ArticleDOI
Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults.
Ann V. Schwartz,Sigurdur Sigurdsson,Trisha F. Hue,Thomas Lang,Tamara B. Harris,Clifford J. Rosen,Eric Vittinghoff,Kristin Siggeirsdottir,Gunnar Sigurdsson,Diana Oskarsdottir,Keerthi Shet,Lisa Palermo,Vilmundur Gudnason,Xiaojuan Li +13 more
TL;DR: Higher marrow fat correlated with lower trabecular, but not cortical, BMD in older women but not men, and higher marrow fat was associated with prevalent vertebral fracture in men, even after adjustment for BMD.
Journal ArticleDOI
Exercise and bone health across the lifespan
TL;DR: Recent work on human ageing and epigenetics suggests that undertaking exercise after the fourth decade of life is still important, given the anti-ageing effect and health benefits provided, potentially occurring via a delay in telomere shortening and modification of DNA methylation patterns associated with ageing.
Journal ArticleDOI
Sexual Activity is Associated with Greater Enjoyment of Life in Older Adults
TL;DR: This is among the first studies to show that well-being is higher among older adults when they are sexually active, and sexual activity is Associated with Greater Enjoyment of Life in Older Adults.
References
More filters
Journal ArticleDOI
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Robert V. Considine,Madhur K. Sinha,Mark L. Heiman,Aidas Kriauciunas,Thomas W. Stephens,Mark R. Nyce,Joanna P. Ohannesian,Cheryl C. Marco,Linda J. McKee,Thomas L. Bauer,Jose F. Caro +10 more
TL;DR: Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production.
Journal ArticleDOI
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
David L. Lacey,Emma Timms,Hong-Lin Tan,Michael J. Kelley,Colin R. Dunstan,Tim Burgess,Robin Elliott,Anne Colombero,Gary Elliott,S. Scully,Hailing Hsu,John K. Sullivan,Nessa Hawkins,E. Davy,C. Capparelli,Alana Eli,Yi-xin Qian,Steve Kaufman,Ildiko Sarosi,Victoria Shalhoub,Giorgio Senaldi,Jane Guo,John M. Delaney,William J. Boyle +23 more
TL;DR: The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGl and OPG are key extracellular regulators of osteoclast development.
Journal ArticleDOI
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Robert M. Neer,Claude D. Arnaud,Jose R. Zanchetta,Richard L. Prince,Gregory A Gaich,Jean-Yves Reginster,Anthony B. Hodsman,Erik Fink Eriksen,Sophia Ish-Shalom,Harry K. Genant,Ouhong Wang,Bruce H. Mitlak +11 more
TL;DR: Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated.
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
Journal ArticleDOI
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings,Javier San Martin,Michael R. McClung,Ethel S. Siris,Richard Eastell,Ian R. Reid,Pierre D. Delmas,Holly B. Zoog,M. Austin,Andrea Wang,Stepan Kutilek,Silvano Adami,Jose R. Zanchetta,Cesar Libanati,Suresh Siddhanti,Claus Christiansen +15 more
TL;DR: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.